New blood test may spot kidney danger in liver patients
NCT ID NCT07452484
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a simple blood test called the Systemic Immune Inflammation Index (SII) can help diagnose and predict acute kidney injury (AKI) in people with liver cirrhosis. AKI is a common and serious complication in cirrhosis, but current tests are often unreliable. The study will follow 100 hospitalized cirrhosis patients, measuring SII over time to see if it detects kidney problems earlier and helps tell apart different causes. If it works, this cheap and widely available test could improve care for a high-risk group.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could provide a simple, cheap blood test to detect kidney injury earlier in cirrhosis patients, improving treatment timing.
- What could go wrong
- This is a small, early-stage study (100 participants) that has not yet started. The SII test may not prove reliable enough for routine use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Mar 2026
An estimate. Start dates often move.
- Expected to finish
-
Oct 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients who develop AKI on top Liver cirrhosis
- Ages
-
18 to 90 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * a) Age ≥18 years b) Confirmed liver cirrhosis (Section 5) c) Hospital admission for acute decompensation or evaluation Exclusion Criteria: * a) ESRD or dialysis dependence. b) Kidney transplant recipient. c) Pregnancy. d) Active malignancy other than HCC. e) Massive GI bleeding within 5 days. f) Use of nephrotoxic drugs within 7 days (NSAIDs, aminoglycosides, amphotericin, contrast media, chemotherapy ). g) Obstructive uropathy . h) Active infection at admission (per infection rule-out protocol). i) Hematologic disorders affecting CBC (e.g., leukemia, aplastic anemia). j) Failure to obtain informed consent.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AKI in cirrhosis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.